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The mismatch between the burden of disease for pregnant women and their infants on the one
hand and investment in developing and testing pharmacological treatments on the other con-
tinues to be a barrier to successfully reducing morbidity and mortality in this important group.
Physiological changes in pregnancy commonly, but not universally, result in increased drug
clearance and decreased exposure to total drugs (bound and unbound to plasma proteins) at a
given dose. In a systematic review in this week’s PLOS Medicine, Shinya Ito and colleagues
draw attention to the relative paucity of knowledge about how these pregnancy-inducedphar-
macokinetic changes impact on clinical outcomes for the mother and fetus after drug treatment
[1]. More studies exploring the pharmacodynamic impacts on clinical efficacy in relation to
these pharmacokinetic changes are urgently needed to inform drug dosing in pregnancy. This
would ensure that pregnant women receive adequate concentrations of an active drug whilst
avoiding unnecessary and excessive exposure of their embryo or fetus to potentially teratogenic
compounds.
Many drugs used in pregnancy are borrowed or repurposed frommainstream therapeutics,
with comprehensive evidence of efficacy and safety in pregnant women often lacking despite
awareness of the pharmacokinetic changes describedby Ito and colleagues. Despite the well-
publicised accounts of teratogenicity—including limb deformities in the fetus—associatedwith
thalidomide (used for hyperemesis) [2] and of the association of diethylstilbestrol (used to pre-
vent early miscarriage) with clear cell adenocarcinoma of the vagina and cervix in daughters of
exposed pregnant women [3], the majority of drugs prescribed in pregnancy are unlicensed for
use in this setting (i.e., used off-label), with much less safety testing than that undertaken for
originalmarketing authorisation. The strengthening of pharmaceutical regulatory procedures
after thalidomidemeans that it is hardly surprising that, for these and other reasons, the phar-
maceutical industry has invested far less in development of new drugs in pregnancy compared
to other areas, where the safety hurdles may be less overwhelming and the duration of treat-
ment longer than the time-limited use in pregnancy. This was enumerated in 2007 through a
review of an industry database reporting that only 17 drugs were under active development for
maternal health indications; this was a fraction of the number for cardiovascular health (660
drugs) and fewer than for a single rare disease such as amyotrophic lateral sclerosis (34 drugs)
[4].
Estimates of medication use in pregnancy using interviews or population-based cohorts
reveal high usage: in one longitudinal study from the United States, 96% of the pregnant
women took prescription medications, 93% self-medicatedwith over-the-counter medications,
PLOS Medicine | DOI:10.1371/journal.pmed.1002161 November 1, 2016 1 / 4
a11111
OPENACCESS
Citation: Chappell LC, David AL (2016) Improving
the Pipeline for Developing and Testing
Pharmacological Treatments in Pregnancy. PLoS
Med 13(11): e1002161. doi:10.1371/journal.
pmed.1002161
Published: November 1, 2016
Copyright: © 2016 Chappell, David. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Funding: LCC is supported by a National Institute
for Health Research Professorship, RP-2014-05-
019. AD is supported by the National Institute for
Health Research University College London
Hospitals Biomedical Research Centre. The funders
had no role in study design, data collection and
analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: AD is Director and cofounder
of Magnus Growth, part of Magnus Life Science, a
company that is aiming to take to market a novel
treatment for fetal growth restriction.
Provenance: Commissioned; not externally peer
reviewed
and 45% used herbal medications [5]; other studies show similar use and reflect the increasing
comorbidities of pregnant women (e.g., diabetes, hypertension, asthma, depression) for which
medication is commonly prescribed. A review of inpatient antenatal prescriptions in a United
Kingdommaternity unit reported that of 235 drugs prescribed, only 16% were licensed for use
in pregnancy; one quarter (24%) of drugs were prescribed off-label but were considered safe by
the manufacturers (e.g., erythromycin, prochlorperazine); for over half (58%) of these 235
drugs, the manufacturer advised caution or contraindication. [6] As the majority of drugs used
by pregnant women are not specifically licensed for use in pregnancy, detailed pharmacoki-
netic and pharmacodynamic studies have often not been undertaken to evaluate efficacy (or
safety) in this distinct physiological setting. Ito and colleagues show that associated alterations
in clinical responses and outcomes, or lack thereof, remain largely unknown. Drugs with mini-
mal side effects, when taken by a nonpregnant adult, may have specific fetotoxic effects when
taken during pregnancy, particularly in the first trimester. For example, many antiepileptic
drugs are associated with fetal neural tube defects and cardiac abnormalities, most likely
because of disruption of folic acid metabolism.However, stopping such drugsmay confer risks
of uncontrolledmaternal seizure activity, which in itself may be life-threatening to mother and
fetus. For some drugs, the pattern of potential teratogenicity is not always predictable from ani-
mal studies and may only reveal itself once the drug is taken by pregnant women. Distinct dif-
ferences in placentation (the human placenta contains one layer of cells betweenmaternal and
fetal blood, whereas most other animal species have multiple layers), placental metabolism,
clearance, and availability of active drugmay be responsible. This reinforces the need for pre-
authorisation research in pregnant women, but undertaking reproductive toxicology studies, to
the extent that will satisfy the regulatory agencies, is time-consuming and expensive.
The difficulty of adequate testing is compounded by the paucity of suitable animal models
for several pregnancy-specificdiseases such as pre-eclampsia and preterm labour, both of
which have heterogeneous pathophysiological pathways in the human and no clear animal
equivalent. The development of novel drugs for these indications—such as atosiban, a competi-
tive oxytocin receptor antagonist for the treatment of threatened preterm labour—has been
beleaguered by controversy, such as uncertainty over appropriate clinical endpoints in trials
(i.e., hard neonatal outcomes rather than prolongation of gestational age) [7] and licensing in
some geographical areas (e.g., Europe) but not others (e.g., in the US) because of differences in
interpretation of trial data. Teratology information services [8] play a key role in screening for
potential new human teratogens, particularly in gathering information about newly marketed
medications.We find ourselves, however, in the relatively unsatisfactory position that, cur-
rently, the use of new drugs in pregnant women creeps into clinical practice and is evaluated
via postmarketing surveillance or registry studies, if at all [9], with pregnancy even being a con-
traindication to participation in many phase IV studies.
Two strands of development are now urgently needed: a greater understanding about the
impact in pregnancy of drugs commonly used for coexistent medical conditions—including
infections (e.g., antibiotics, antivirals, antimalarials) and chronic diseases (e.g., hypertension,
epilepsy, asthma, diabetes, rheumatological diseases)—and a coordinated strategy to invest in
the development of drugs for pregnancy-specific conditions such as pre-eclampsia, fetal growth
restriction, and preterm labour, where disease-modifyingpharmacological treatments could
have a major impact on ameliorating short- and long-term adverse outcomes for mother and
baby. The importance of the intrauterine environment on adult health is well known [10], but
estimating the cost-effectiveness of drugs given in pregnancy that ameliorate adult disease is
challenging. Databases for the “repurposing” of drugs with licenses for use in obstetrics are
emerging, but further work is needed to understand the potential market revenues for obstetric
therapeutics and to encourage investment from the pharmaceutical industry.
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Clinical trials in pregnant women can be challenging and require collaborative efforts
across clinical and research networks along with the active involvement of the pharmaceutical
industry. In parallel, there is a need for ongoing postmarketing surveillance (with good linkage
to paediatric developmental outcome data) of drugs licensed for other medical conditions
that are used commonly but without adequate knowledge on dosing (e.g., antibiotics, or low-
molecular-weight heparin for thromboprophylaxis) or used rarely but where there are com-
pelling reasons to continue treatment (e.g., biologics). New European Union regulations
introduced in 2007 mandated the requirement for a Paediatric Investigational Plan for all
applications for marketing authorisation for newmedicines (unless the medicine is exempt
because of a deferral or waiver) [11]. Such an obligation could be proposed for pregnancy at a
legislative level to increase the formal testing of medicines on women who are pregnant. This
commitment would require considerable financial resources and willingness for change, but
the ongoing economic, health, and psychosocial costs associated with diseases in pregnancy
necessitate a transformational approach. The recent changes to the US Food and Drug
Administration rules on labelling of medications in pregnancy and lactation, which replaces
the previous letter categories (A, B, C, D, X) with an informative narrative description of
potential benefits and risks and establishes links to pregnancy exposure registries, are to be
welcomed [12]. We and others [13] now propose that the following avenues (Box 1) need to
be explored by all those involved with medical care for women of reproductive age and the
lifelong consequences of pregnancy-associated diseases to ensure that this gap in our research
and clinical knowledge is addressed.
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Box 1. Strategies to Improve the Development and Testing of
Pharmacological Treatments in Pregnancy
• Development of appropriate models in which to test placental transfer and evaluate
teratogenesis
• Funding initiatives for pharmacokinetic and pharmacodynamic studies of existing
drugs, particularly those unlicensed but commonly used
• Consideration of novel approaches to overcome current ethical, regulatory, and deliv-
erability hurdles for clinical trials in pregnancy
• Institution of funded registries (with obligatory reporting), particularly for drugs for
which there is overwhelming clinical need but limited safety data (e.g., new antiepilep-
tic drugs; biologics), with short- and long-termmaternal and child neurodevelopmen-
tal follow-up
• Establishment of a Maternity Investigational Plan to match that introduced across
Europe for medicines in children
• Involvement of pregnant women and their families in all such initiatives such that ethi-
cal risks and benefits are explored openly and transparently.
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